Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 5/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2088251 | 0.85 | ALDH1A1 (0.50) | GCKRAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL2089387 | 0.84 | FBP1 (0.52) | GCKFBP1RAB9AMAPTNPC1 | |
| SCHEMBL2089403 | 0.82 | CHRNB2 (0.40) | GCKRAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL2089275 | 0.78 | NPC1 (0.46) | RAB9AMAPTNPC1SMN1; SMN2KDM4E | |
| SCHEMBL2088000 | 0.74 | FBP1 (0.48) | GCKFBP1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL2088223 | 0.74 | TSHR (0.48) | MAPTNPC1SMN1; SMN2TP53HSD17B10 | |
| SCHEMBL2087730 | 0.73 | FBP1 (0.38) | GCKFBP1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2087196 | 0.73 | PLAU (0.37) | GCKFBP1MAPTSMN1; SMN2PLK1 | |
| SCHEMBL2088872 | 0.72 | FBP1 (0.50) | GCKFBP1RAB9AMAPTNPC1 | |
| SCHEMBL2087527 | 0.72 | SMN1; SMN2 (0.40) | RAB9ANPC1SMN1; SMN2PRKD3MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163778-B2 | Pyridines as FBPase inhibitors for treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2227452-A2 | PYRIDINE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009068468-A2 | PYRIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | WO | disclosed |
| US-20090143439-A1 | NEW PYRIDINES AS FBPASE INHIBITORS FOR TREATMENT OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143439-A1 | NEW PYRIDINES AS FBPASE INHIBITORS FOR TREATMENT OF DIABETES | FBP1, PDXK, G6PC1 | GCK 24/4885FBP1 1/4885RAB9A 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.